The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1631
August 23, 2021
View Complete Issue         Table of Contents 2019 
Voclosporin (Lupkynis) for Lupus Nephritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Voclosporin (Lupkynis) for Lupus Nephritis
August 23, 2021 (Issue: 1631)
Voclosporin (Lupkynis – Aurinia), an oral calcineurin inhibitor, has been approved by the FDA for use in combination with the antimetabolite immunosuppressant mycophenolate mofetil (Cellcept, and generics) and a corticosteroid for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Voclosporin (Lupkynis) for Lupus Nephritis
Article code: 1631e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.